In contrast, 1,25OHD upregulated RUNX2 expression at 3 days with the 10 and 50 nM 1,25OHD compared with OM treatment (p < 0.0001), and there was a tendency for 1,25OHD to increase its expression as a dose-response manner (Figure 1C), although no significant difference in RUNX2 expression was found at 7 days among the treatments (Figure 1D). This evidence concerns the gene RUNX2 and ocular melanoma.